Form 4: Alignment Healthcare President Sells 30,000 Shares Under Pre-Arranged Trading Plan

Alignment Healthcare, Inc. President, Dawn Christine Maroney, sold 30,000 shares of common stock for a weighted-average price of $13.4449 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dawn Christine Maroney, President of Alignment Healthcare, Inc. (ALHC), reported the sale of 30,000 shares of common stock.
• The transaction occurred on July 14, 2025, at a weighted-average price of $13.4449 per share, with individual sales ranging from $13.21 to $13.68 per share.
• The sale was conducted pursuant to a Rule 10b5-1(c) trading plan, which was adopted on November 25, 2024.
• Following this transaction, Dawn Christine Maroney beneficially owns 2,042,899 shares of Alignment Healthcare, Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While an insider sale can be perceived negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns that it is based on adverse non-public information.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction for personal financial management rather than a reaction to new, negative material non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity exposure of a key executive, which can sometimes be perceived negatively by the market as it may signal a lack of conviction in future stock price appreciation.

Risks

• No specific risks are explicitly mentioned in the document beyond the general implications of an insider stock sale.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider stock transaction by a company executive. Such transactions are common for personal financial planning and do not inherently reflect broader industry trends unless a pattern of similar sales emerges across the healthcare sector.

Stakeholder Impact

• Shareholders: The transaction results in a minor reduction in direct insider ownership, which is generally not a significant concern given the pre-planned nature of the sale and the remaining substantial holdings.

Key Dates

Recommendation

Keywords

Alignment Healthcare, ALHC, Form 4, insider trading, stock sale, executive compensation, Rule 10b5-1, Dawn Maroney